An interventional study of Doppler-guided early mobilization in Arterial Ischemic Stroke, sponsored by Unidade Local de Saúde de Coimbra, EPE. Recruiting at 7 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by Unidade Local de Saúde de Coimbra, EPE · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Ischemic Stroke with a site in Portugal — 8 open to participants now, 11 under way, 2 of them phase 3. Ischemic Stroke · Portugal.
Among the 27 studies in Ischemic Stroke with a site in Portugal, this one is the 9th largest by planned enrollment of the 20 interventional ones that give a count, is one of 4 that started in 2025, is one of 9 with no phase, reaches primary completion later than 3 of the 10 other live ones, and was the 26th registered.
2,619 studies on the registry are indexed under Ischemic Stroke; 978 are open to participants now.
Browse Ischemic Stroke studies →8 of the 27 studies in Ischemic Stroke with a site in Portugal are open now. Recruiting first, the newest first:
Corxel Pharmaceuticals · Sites in Portugal, United States, Belgium and 18 more countries
Ages 18–90
Insel Gruppe AG, University Hospital Bern · Sites in Portugal, Austria, Belgium and 9 more countries
Ages 18+
University of L'Aquila · Sites in Portugal, Croatia, Denmark and 12 more countries
Ages 18+
Insel Gruppe AG, University Hospital Bern · Sites in Portugal, Austria, Belgium and 12 more countries
Ages 18+
Biotronik SE & Co. KG · Sites in Portugal, Australia, Czechia and 6 more countries
Ages 18+
A study can be open while its sites in Portugal have not opened yet or have stopped. Only those recruiting at a site in Portugal →
Of the 662 Ischemic Stroke studies recruiting now, 396 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 42 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 9 · Phase 4 1
First in 2006; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,300 is above the median of 120 across 1,781 interventional studies indexed under Ischemic Stroke.
Median enrollment 1,021 across the 20 interventional studies, 1,282 across the 7 observational. Of the 16 that completed or were terminated, 5 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 27 have an industry lead sponsor. The 10 most frequent:
Unidade Local de Saúde de Coimbra, EPE is the lead sponsor of 5 studies on the registry; 3 are open to participants now.
Unidade Local de Saúde de Coimbra, EPE has 1 study filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
3 of the studies in Ischemic Stroke with a site in Portugal that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07232498Unidade Local de Saúde de Coimbra, EPEEarly Doppler-Assisted Mobilization in Adults After Acute Ischemic Stroke | 2026-12 |
| NCT06823466University of L'AquilaAdvancing Knowledge in Ischemic Stroke Patients on Oral Anticoagulants | 2027-02-12 |
| NCT04075084Biotronik SE & Co. KGObservation of Clinical Routine Care for Patients With BIOTRONIK Implantable Cardiac Monitors (ICMs) | 2027-05-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 27 studies in Ischemic Stroke with a site in Portugal, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Post-stroke mobilization remains a subject of ongoing debate. While early mobilization-particularly the first out-of-bed mobilization-has been associated with reduced systemic complications and earlier rehabilitation, it also carries potential risks, such as neurological deterioration in the presence of hemodynamic instability.
In this study, the primary aim is to investigate whether early mobilization, guided by hemodynamic evaluation after acute ischemic stroke offers superior outcomes compared to standard clinical care.
Cerebrovascular diseases are the leading cause of death in Portugal and one of the most significant contributors to morbidity and disability.
Early mobilization after stroke is debated due to its potential benefits-such as fewer systemic complications and faster rehabilitation-and risks, particularly in patients with hemodynamic instability.
International guidelines support for early mobilization tailored to the patient's neurological status; however, the scientific evidence remains limited, resulting in heterogeneous practices across institutions.
Previous studies have highlighted the insufficient consideration of hemodynamic status when determining the timing of initial mobilization.
This study is a phase 3, pragmatic, prospective, multicenter randomized controlled trial with blinded outcome assessment (PROBE design: Prospective, Randomized, Open-label, Blinded Outcome Assessment), with an anticipated total duration of 36 months.
The study will be conducted in the Neurology Departments of the participating hospital centers and aims to: (1) evaluate the superiority of early mobilization guided by hemodynamic assessment following acute ischemic stroke, compared to standard clinical practice; (2) assess neurological deficits, quality of life, and cognitive function at three months, as well as hospital length of stay, blood pressure profile evolution, patient-reported outcome measures (PROMs), and employability; (3) compare adverse events between patients undergoing Doppler-guided early mobilization and those in the control group, including hospital-acquired infections, neurological deterioration, hemorrhagic transformation, and mortality.
Patients randomized to the intervention group will be mobilized according to carotid and transcranial Doppler ultrasound findings. In the presence of hemodynamic impairment, patients will undergo progressive mobilization, aiming to be out of bed by days 5 to 7 post-stroke, with gait training as neurologically feasible. In the absence of such findings, patients will begin mobilization immediately after the examination, with the goal of being out of bed and seated within 48 hours, including gait training when possible. Functional status at three months will be assessed using the modified Rankin Scale (mRS), which constitutes the study's primary endpoint.
All data collection procedures will follow formal and ethical research standards, ensuring that all informed participants voluntarily, anonymously, consent to take part in the study, with confidentiality maintained and no costs or harm to participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with ischemic stroke will be mobilized based on the results of carotid and transcranial Doppler ultrasound examinations. If significant hemodynamic alterations are identified, such as stenosis ≥70% or intracranial occlusions, mobilization will be gradually introduced up to the 5th-7th day post-event. In the absence of such alterations, mobilization will begin immediately, with out-of-bed transfer to a chair within 48 hours and gait training, if clinically feasible.
Procedure: Doppler-guided early mobilization
Patients with ischemic stroke are mobilized according to standard clinical practice, without considering hemodynamic assessment results from Doppler ultrasound. Mobilization is introduced gradually, guided by the patient's clinical tolerance.
Individualized early mobilization after ischemic stroke, guided by hemodynamic assessment using carotid and transcranial Doppler ultrasound. The type and timing of mobilization are adjusted according to the presence of significant hemodynamic alterations.
Functional status at 3 months after ischemic stroke
Functional status assessment at 3 months after ischemic stroke, using the modified Rankin Scale (mRS), analyzed on an ordinal scale (0-6), to measure the degree of dependence/functional impairment. Score ranges: 0-no residual symptoms (better outcome); 1. no significant disability; 2. slight disability; 3. moderate disability; 4. moderately severe disability; 5. severe disability; 6. death (worse outcome).
Time frame: 3 months post-stroke
Neurological Assessment (NIHSS Scale)
Neurological assessment on the 7th day after ischemic stroke, measured using the National Institutes of Health Stroke Scale score (NIHSS, from 0-42) to evaluate the severity of neurological deficits. Score ranges: 0-4: Minor Stroke (better outcome); 5-15: Moderate Stroke; 16-20: Moderate to Severe Stroke; 21-42: Severe Stroke (worse outcome).
Time frame: Day 0, 48 hours, Day 7 and Month 3
Development of hospital-acquired infections
Incidence of infections acquired during hospitalization
Time frame: Up to 7 days
Vital signs - Body temperature
Measurement of body temperature in degrees Celsius at the time of the visit
Time frame: Day 0, 48 hours, Day 7
Vital signs - Systolic and diastolic blood pressure
Measurement of blood pressure in mmHg at the time of the visit
Time frame: Day 0, 48 hours, Day 7
Vital signs - Heart rate
Measurement of heart rate in beats per minute (bpm) at the time of the visit
Time frame: Day 0, 48 hours, Day 7
Mortality
Mortality rate (%)
Time frame: 3 months
EQ-5D-5L
An instrument to describe and value health across a wide range of disease areas. 5-level EQ-5D (EuroQol instrument with 5 dimensions and 5 levels) version with five dimensions (five levels, categorical options): mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Score ranges: 1. I have no problems ...walking/dressing, etc (better outcome); 2. I have some problems ...walking/dressing, etc; 3. I have moderate problems ...walking/dressing, etc; 4. I have severe problems ...walking/dressing, etc; 5. I have extreme problems ...walking/dressing, etc (worse outcome).
Time frame: 3 months
Recurrent stroke assessment
Assessment of stroke recurrence after the first event, specifying the type into categories (no recurrence, new transient ischemic attack, new ischemic stroke, hemorrhagic stroke) and the time interval between events.
Time frame: Day 0, 48 hours, Day 7
MONTREAL COGNITIVE ASSESSMENT (MoCA)
A brief cognitive screening tool used to assess mild cognitive impairment, score from 0-30. Score ranges: \< 19: moderate to severe cognitive impairment (worse outcome); 19-25: mild cognitive impairment; \> 26: normal (better outcome).
Time frame: Month 3
Hospital Anxiety and Depression Scale (HADS)
Final score of the scale that assesses anxiety and depression in patients, especially those with physical illnesses (score from 0-21, wiht 14 items and each item with four-point scale, 0-3). Score ranges: 0-7: Normal - No significant symptoms of anxiety or depression (better outcome); 8-10: Borderline/Mild - Presence of symptoms that may require attention; 11 or higher: Probable Case/Severe - Clinically significan psychological disorder or "probable case" (worse outcome).
Time frame: 3 months
Mobility assessment
Assessment of participant mobility according to categories (not yet mobilized, transfers to chair, ambulating)
Time frame: 48 hours, Day 7, Month 3.
Breath Holding Index (BHI) - measure 1
Non-invasive method used to assess cerebrovascular reactivity, specifically the ability of the brain's blood vessels to adjust to changes in carbon dioxide levels. Three attempts will be performed for each participant with measurements of: * (a) baseline mean flow velocity before the apnea test (cm/sec)
Time frame: Before 48 hours or Day 7 (if not performed previously)
Breath Holding Index (BHI) - measure 2
Non-invasive method used to assess cerebrovascular reactivity, specifically the ability of the brain's blood vessels to adjust to changes in carbon dioxide levels. Three attempts will be performed for each participant with measurements of: * (b) mean flow velocity at the end of the apnea test (cm/sec).
Time frame: Before 48 hours or Day 7 (if not performed previously)
Breath Holding Index (BHI) - measure 3
Non-invasive method used to assess cerebrovascular reactivity, specifically the ability of the brain's blood vessels to adjust to changes in carbon dioxide levels. Three attempts will be performed for each participant with measurements of: * (c) apnea duration (sec).
Time frame: Before 48 hours or Day 7 (if not performed previously)
Hemorrhagic transformation
Type of ischemic stroke complication according to hemorrhage infarction (HI) /parenchymal hemorrhage (PH) levels in brain tissue. Score: 0- No complication HI1- Hemorrhage infarction 1; HI2- Hemorrhage infarction 2; PH1- Parenchymal hemorrhage 1; PH2- Parenchymal hemorrhage 2; No follow-up CT/MRI performed.
Time frame: 48 hours, Day 7
Early Mobilization Decision (<48h)
Ultrasound-guided (US) mobilization: early mobilization (\<48h) if no cerebral hemodynamic impairment in US; Decision - yes or no? (only for interventional group)
Time frame: Day 0
Hospitalization duration
Number of days of hospitalization
Time frame: Month 3
White matter lesions in neuroimaging
White matter legions in neuroimaging - ARWMC scale: 0-no lesions (better outcome); 1-focal lesions; 2-beginning confluence of lesions; 3-diffuse involvement of the entire region, with or without involvement of U fibers (worse outcome).
Time frame: Day 0
Plan to share: No — Data will be irreversibly anonymized and exclusively handled by researchers involved in the study.
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Dec 2026, 18 months after the start.
Of 573 non-industry interventional studies with no phase under Ischemic Stroke, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 18 months is below that.
Counting every sponsor, half of 654 studies reached it within 27 months; a quarter within 14 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Unidade Local de Saúde de Coimbra, EPE